2160.T Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 02:15):

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally...

Stats
Today's Volume	504 500
Average Volume	1.06M
Market Cap	121.76B
EPS	¥0 ( 2024-02-13 )
Next earnings date	( ¥0 ) 2024-05-14
Last Dividend	¥0 ( N/A )
Next Dividend	¥0 ( N/A )
P/E	14.74
ATR14	¥1.240 (0.05%)

Volume Correlation

Long: 0.27 (neutral)

Short: -0.98 (very strong negative)

Signal:(55.783) Neutral

GNI Group Ltd. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

GNI Group Ltd. Correlation - Currency/Commodity

-0.45
( neutral )

-0.13
( neutral )

-0.76
( moderate negative )

0.22
( neutral )

0.28
( neutral )

-0.35
( neutral )

GNI Group Ltd. Financials

Annual	2023
Revenue:	¥26.01B
Gross Profit:	¥22.43B (86.24 %)
EPS:	¥169.50

Q4	2023
Revenue:	¥5.46B
Gross Profit:	¥4.25B (77.85 %)
EPS:	¥121.16

Q3	2023
Revenue:	¥6.45B
Gross Profit:	¥5.42B (84.06 %)
EPS:	¥11.68

Q2	2023
Revenue:	¥9.89B
Gross Profit:	¥9.12B (92.24 %)
EPS:	¥34.99

Financial Reports:

No articles found.

GNI Group Ltd.

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.